Activity of Newer Fluoroquinolones in Vitro Against Gram-positive Bacteria

Overview

Journal Drugs

Specialty Pharmacology

Date 1999 Dec 20

PMID 10553701

Citations 3

Authors

G M Eliopoulos

Affiliations

Soon will be listed here.

Abstract

Several newer fluoroquinolones, which have been recently introduced or are under investigation, display substantially greater potency against gram-positive organisms than the older generation agents of this class. Nevertheless, for problem organisms including methicillin-resistant strains of Staphylococcus aureus and many Enterococcus faecium, concentrations of newer antimicrobials required to inhibit 90% of organisms in the collections studied remain above those that are projected to be achievable with clinical use. Nevertheless, enhanced potency of several newer quinolones may result in a favourable pharmacodynamic profile leading to improved outcomes against gram-positive infections and possibly to the delayed or diminished emergence of resistance to these agents.

Citing Articles

Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.

Valenzuela M, Domenech M, Mateos-Martinez P, Gonzalez-Camacho F, Campa A, Garcia M PLoS One. 2020; 15(11):e0241780.

PMID: 33141832 PMC: 7608930. DOI: 10.1371/journal.pone.0241780.

Photodegradation of moxifloxacin in aqueous and organic solvents: a kinetic study.

Ahmad I, Bano R, Musharraf S, Ahmed S, Sheraz M, Ul Arfeen Q AAPS PharmSciTech. 2014; 15(6):1588-97.

PMID: 25139764 PMC: 4245426. DOI: 10.1208/s12249-014-0184-x.

Efflux-mediated resistance to fluoroquinolones in gram-positive bacteria and the mycobacteria.

Poole K Antimicrob Agents Chemother. 2000; 44(10):2595-9.

PMID: 10991829 PMC: 90120. DOI: 10.1128/AAC.44.10.2595-2599.2000.

References

Sato K, Hoshino K, Tanaka M, Hayakawa I, Osada Y . Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992; 36(7):1491-8. PMC: 191610. DOI: 10.1128/AAC.36.7.1491. View

Marshall S, Jones R, Murray P, Washington J, Allen S, Gerlach E . In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. J Antimicrob Chemother. 1993; 32(6):877-84. DOI: 10.1093/jac/32.6.877. View

Souli M, Wennersten C, Eliopoulos G . In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens. Int J Antimicrob Agents. 1998; 10(1):23-30. DOI: 10.1016/s0924-8579(98)00020-x. View

Woodcock J, Andrews J, Boswell F, Brenwald N, Wise R . In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother. 1997; 41(1):101-6. PMC: 163668. DOI: 10.1128/AAC.41.1.101. View

Wise R, Andrews J, Matthews R, Wolstenholme M . The in-vitro activity of two new quinolones: rufloxacin and MF 961. J Antimicrob Chemother. 1992; 29(6):649-60. DOI: 10.1093/jac/29.6.649. View

Marco F, Jones R, Hoban D, Pignatari A, Yamane N, Frei R . In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study. J Antimicrob Chemother. 1994; 33(3):647-54. DOI: 10.1093/jac/33.3.647. View

Cunha B, Qadri S, Ueno Y, Walters E, Domenico P . Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates. J Antimicrob Chemother. 1997; 39 Suppl B:29-34. DOI: 10.1093/jac/39.suppl_2.29. View

Felmingham D, Robbins M, Ingley K, MATHIAS I, Bhogal H, Leakey A . In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997; 39 Suppl B:43-9. DOI: 10.1093/jac/39.suppl_2.43. View

Nakane T, Iyobe S, Sato K, Mitsuhashi S . In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother. 1995; 39(12):2822-6. PMC: 163041. DOI: 10.1128/AAC.39.12.2822. View

10.

Rolston K, Ho D, LeBlanc B, Streeter H, Dvorak T . In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother. 1997; 39 Suppl B:15-22. DOI: 10.1093/jac/39.suppl_2.15. View

11.

Fukuoka Y, Ikeda Y, Yamashiro Y, Takahata M, Todo Y, Narita H . In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Antimicrob Agents Chemother. 1993; 37(3):384-92. PMC: 187681. DOI: 10.1128/AAC.37.3.384. View

12.

Wise R, Brenwald N, Andrews J, Boswell F . The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. J Antimicrob Chemother. 1997; 39(4):447-52. DOI: 10.1093/jac/39.4.447. View

13.

Eliopoulos G, Wennersten C, Moellering Jr R . Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis. 1996; 25(1):35-41. DOI: 10.1016/0732-8893(96)00069-7. View

14.

Nishijima S, Namura S, Akamatsu H, Kawai S, Asada Y, Kawabata S . In vitro activity of nadifloxacin against both methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus from patients with skin infections. Drugs. 1995; 49 Suppl 2:230-2. DOI: 10.2165/00003495-199500492-00051. View

15.

Muratani T, Inoue M, Mitsuhashi S . In vitro activity of T-3761, a new fluoroquinolone. Antimicrob Agents Chemother. 1992; 36(10):2293-303. PMC: 245492. DOI: 10.1128/AAC.36.10.2293. View

16.

Allemandi D, Alovero F, Manzo R . In-vitro activity of new sulphanilil fluoroquinolones against Staphylococcus aureus. J Antimicrob Chemother. 1994; 34(2):261-5. DOI: 10.1093/jac/34.2.261. View

17.

Ito T, Otsuki M, Nishino T . In vitro antibacterial activity of Q-35, a new fluoroquinolone. Antimicrob Agents Chemother. 1992; 36(8):1708-14. PMC: 192035. DOI: 10.1128/AAC.36.8.1708. View

18.

Kim J, Choi K, Kim J, Lee J, Choi E, Kim B . In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone. J Antimicrob Chemother. 1998; 41(2):223-9. DOI: 10.1093/jac/41.2.223. View

19.

Eliopoulos G, Wennersten C, Cole G, Chu D, Pizzuti D, Moellering Jr R . In vitro activity of A-86719.1, a novel 2-pyridone antimicrobial agent. Antimicrob Agents Chemother. 1995; 39(4):850-3. PMC: 162641. DOI: 10.1128/AAC.39.4.850. View

20.

Bauernfeind A . Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1998; 40(5):639-51. DOI: 10.1093/jac/40.5.639. View